A major challenge in determining the manufacturability of a candidate therapeutic is determining and optimizing the mechanisms behind its crystallization process.
A major challenge in determining the manufacturability of a candidate therapeutic is determining and optimizing the mechanisms behind its crystallization process, as different crystal shapes can have large impacts on the solubility, stability and bioavailability of the API. This pre-formulation phase is growing in prominence as a critical step in the pharmaceutical development process. It is now recognized that the decrease in productivity in the pharmaceutical industry is partly due to poor physical and material properties of the drug candidates.
Join us for this live webinar where we will discuss:
Presented by:
Marc MEUNIER, Ph.D.
Sr. Solution Scientist
BIOVIA, Dassault Systemes
Fellow of the BIOVIA Science Council